Perrigo Consumer Product Growth Slows While Overall Sales Climb
This article was originally published in The Tan Sheet
Executive Summary
The private labeler reported $53 million in new product sales for its Q2, but says the return to stores of branded OTCs, which had been recalled due to manufacturing problems, continues to diminish its consumer health product sales growth.
You may also be interested in...
“Perfect Storm” Flattens Perrigo Consumer Sales, Cuts Income 57%
The harsh winter, weak cough/cold season and poor retail environment created “a difficult quarter for our consumer business,” which reported flat sales, says Perrigo CEO Joseph Papa. The firm also reported a continued delay in re-launching generic versions of the Mucinex expectorant line.
“Perfect Storm” Flattens Perrigo Consumer Sales, Cuts Income 57%
The harsh winter, weak cough/cold season and poor retail environment created “a difficult quarter for our consumer business,” which reported flat sales, says Perrigo CEO Joseph Papa. The firm also reported a continued delay in re-launching generic versions of the Mucinex expectorant line.
Perrigo Expands Consumer Business Down Under, Rx Growth Looks Up
The OTC private-label sales leader acquires OTC and nutritional brands marketed down under. The Dublin-based firm hopes to add to its specialty generics offerings and its “promotable” brands with tuck-in acquisitions.